Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Suspension of ODE activities

This article was originally published in The Gray Sheet

Executive Summary

FDA plans to announce in an upcoming Federal Register notice a two- to three-week suspension of the Office of Device Evaluation's activities, along with a suspension of the office's statutory review clock, to allow for relocation of ODE offices. The move from 1390 Piccard Drive to 9200 Corporate Blvd. in Gaithersburg, Maryland is expected to take place in October ("The Gray Sheet" Aug. 15, In Brief). The notice will be similar to one that was published in 1989 when it moved from Silver Spring, Maryland to its current location ("The Gray Sheet" May 29, 1989, In Brief)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel